Compare Mesoblast Limited (MESO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Toronto-Dominion Bank — how do they compare? Mesoblast Limited trades at $16.3 (market cap $2.17B), while Toronto-Dominion Bank trades at $120.42 (market cap $197.03B). The key difference: Toronto-Dominion Bank is far larger — about 90.8× Mesoblast Limited's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TD | |
|---|---|---|
Market Cap | $2.17B | $197.03B |
Sector | Technology | Financials |
52-Week High | $20.96 | $124.80 |
52-Week Low | $12.88 | $72.55 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TD stock trades at $120.56, down 2.46% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.74 exceeding the $1.63 estimate. Revenue growth remains steady, increasing from $56.3B in 2024 to $61.3B in 2025, while net income margin improved significantly to 33.51%.
Analyst consensus is bullish with a $153 price target representing 27% upside potential. Key risks include volatile cash flow patterns and high debt levels, while opportunities lie in continued earnings outperformance and dividend stability. The stock presents a compelling value proposition for investors seeking banking sector exposure with growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
